1. |
- Agudelo, Leandro Z., et al.
(författare)
-
Metabolic resilience is encoded in genome plasticity
- 2021
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Metabolism plays a central role in evolution, as resource conservation is a selective pressure for fitness and survival.Resource-driven adaptations offer a good model to study evolutionary innovation more broadly. It remains unknown howresource-driven optimization of genome function integrates chromatin architecture with transcriptional phase transitions.Here we show that tuning of genome architecture and heterotypic transcriptional condensates mediate resilience tonutrient limitation. Network genomic integration of phenotypic, structural, and functional relationships reveals that fattissue promotes organismal adaptations through metabolic acceleration chromatin domains and heterotypic PGC1Acondensates. We find evolutionary adaptations in several dimensions; low conservation of amino acid residues withinprotein disorder regions, nonrandom chromatin location of metabolic acceleration domains, condensate-chromatin stabilitythrough cis-regulatory anchoring and encoding of genome plasticity in radial chromatin organization. We show thatenvironmental tuning of these adaptations leads to fasting endurance, through efficient nuclear compartmentalization oflipid metabolic regions, and, locally, human-specific burst kinetics of lipid cycling genes. This process reduces oxidativestress, and fatty-acid mediated cellular acidification, enabling endurance of condensate chromatin conformations.Comparative genomics of genetic and diet perturbations reveal mammalian convergence of phenotype and structuralrelationships, along with loss of transcriptional control by diet-induced obesity. Further, we find that radial transcriptionalorganization is encoded in functional divergence of metabolic disease variant-hubs, heterotypic condensate composition,and protein residues sensing metabolic variation. During fuel restriction, these features license the formation of largeheterotypic condensates that buffer proton excess, and shift viscoelasticity for condensate endurance. This mechanismmaintains physiological pH, reduces pH-resilient inflammatory gene programs, and enables genome plasticity throughtranscriptionally driven cell-specific chromatin contacts. In vivo manipulation of this circuit promotes fasting-likeadaptations with heterotypic nuclear compartments, metabolic and cell-specific homeostasis. In sum, we uncover here ageneral principle by which transcription uses environmental fluctuations for genome function, and demonstrate howresource conservation optimizes transcriptional self-organization through robust feedback integrators, highlighting obesityas an inhibitor of genome plasticity relevant for many diseases.
|
|
2. |
- Agudelo, Leandro Z
(författare)
-
Skeletal muscle PGC-1α1 and KAT enzymes at the intersection between depression and metabolic disease
- 2017
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Depression and metabolic diseases are leading causes of disability and major contributors to socioeconomic burden worldwide. Physical activity exerts many beneficial effects that confer direct health improvement in individuals suffering from these disorders. However, the molecular mechanisms underlying the influence of different components of exercise interventions remain unknown. To isolate the impact of skeletal muscle conditioning on stress-induced depression, we used transgenic models that exhibit many of the chronic adaptations to aerobic exercise in skeletal muscle. Here, we show a mechanism by which skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. PGC-1α1 acts in concert with PPARα/δ transcription factors to induce the expression of kynurenine aminotransferases in skeletal muscle. The activity of this pathway diverts the metabolism of stress-induced kynurenine to kynurenic acid. Since kynurenic acid is unable to cross the blood brain barrier, this peripheral shift protects the brain from stress-induced accumulation of kynurenines. In addition, we further show that skeletal muscle PGC-1α1 and kynurenine aminotransferases are part of the physiological adaptations to aerobic exercise in both rodents and humans. Given that exercise-mediated activation of this pathway leads to peripheral accumulation of kynurenic acid, we evaluated the physiological role of this metabolite in modulating energy homeostasis. Here, we describe that kynurenic acid plays a role in systemic energy homeostasis through the regulation of adipose tissue function and inflammation. Kynurenic acid induces the expression of lipid metabolism, thermogenic and anti-inflammatory gene networks in the white adipose compartment. This reduces body-weight gain and improves glucose tolerance in animals fed a high-fat diet. Mechanistic studies in primary adipocytes show that kynurenic acid activates the G protein-coupled receptor 35. Downstream signaling of this activation is mediated through Ca2+, ERK, CREB and PGC-1α1 stabilization. Finally, activation of GPR35 by kynurenic acid induces the expression of RGS14, which sensitizes β-adrenergic response to specific agonists. In sum, this work uncovers a previously unknown function of PGC-1α1 in skeletal muscle and kynurenic acid in white adipose tissue. Targeting this metabolic node has great potential for the treatment of depression and metabolic diseases such as type-2 diabetes.
|
|
3. |
- Atabaki-Pasdar, Naeimeh, et al.
(författare)
-
Inferring causal pathways between metabolic processes and liver fat accumulation: an IMI DIRECT study
- 2021
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) often co-occur. Defining causal pathways underlying this relationship may help optimize the prevention and treatment of both diseases. Thus, we assessed the strength and magnitude of the putative causal pathways linking dysglycemia and fatty liver, using a combination of causal inference methods.Measures of glycemia, insulin dynamics, magnetic resonance imaging (MRI)-derived abdominal and liver fat content, serological biomarkers, lifestyle, and anthropometry were obtained in participants from the IMI DIRECT cohorts (n=795 with new onset T2D and 2234 individuals free from diabetes). UK Biobank (n=3641) was used for modelling and replication purposes. Bayesian networks were employed to infer causal pathways, with causal validation using two-sample Mendelian randomization.Bayesian networks fitted to IMI DIRECT data identified higher basal insulin secretion rate (BasalISR) and MRI-derived excess visceral fat (VAT) accumulation as the features of dysmetabolism most likely to cause liver fat accumulation; the unconditional probability of fatty liver (>5%) increased significantly when conditioning on high levels of BasalISR and VAT (by 23%, 32% respectively; 40% for both). Analyses in UK Biobank yielded comparable results. MR confirmed most causal pathways predicted by the Bayesian networks.Here, BasalISR had the highest causal effect on fatty liver predisposition, providing mechanistic evidence underpinning the established association of NAFLD and T2D. BasalISR may represent a pragmatic biomarker for NAFLD prediction in clinical practice.Competing Interest StatementHR is an employee and shareholder of Sanofi. MIM: The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. MIM has served on advisory panels for Pfizer, NovoNordisk and Zoe Global, has received honoraria from Merck, Pfizer, Novo Nordisk and Eli Lilly, and research funding from Abbvie, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, NovoNordisk, Pfizer, Roche, Sanofi Aventis, Servier, and Takeda. As of June 2019, MIM is an employee of Genentech, and a holder of Roche stock. AM is a consultant for Lilly and has received research grants from several diabetes drug companies. PWF has received research grants from numerous diabetes drug companies and fess as consultant from Novo Nordisk, Lilly, and Zoe Global Ltd. He is currently the Scientific Director in Patient Care at the Novo Nordisk Foundation. Other authors declare non competing interests.Funding StatementThe work leading to this publication has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement 115317 (DIRECT) resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. NAP is supported in part by Henning och Johan Throne-Holsts Foundation, Hans Werthen Foundation, an IRC award from the Swedish Foundation for Strategic Research and a European Research Council award ERC-2015-CoG - 681742_NASCENT. HPM is supported by an IRC award from the Swedish Foundation for Strategic Research and a European Research Council award ERC-2015-CoG - 681742_NASCENT. AGJ is supported by an NIHR Clinician Scientist award (17/0005624). RK is funded by the Novo Nordisk Foundation (NNF18OC0031650) as part of a postdoctoral fellowship, an IRC award from the Swedish Foundation for Strategic Research and a European Research Council award ERC-2015-CoG - 681742_NASCENT. AK, PM, HF, JF and GNG are supported by an IRC award from the Swedish Foundation for Strategic Research and a European Research Council award ERC-2015-CoG - 681742_NASCENT. TJM is funded by an NIHR clinical senior lecturer fellowship. S.Bru acknowledges support from the Novo Nordisk Foundation (grants NNF17OC0027594 and NNF14CC0001). ATH is a Wellcome Trust Senior Investigator and is also supported by the NIHR Exeter Clinical Research Facility. JMS acknowledges support from Science for Life Laboratory (Plasma Profiling Facility), Knut and Alice Wallenberg Foundation (Human Protein Atlas) and Erling-Persson Foundation (KTH Centre for Precision Medicine). MIM is supported by the following grants; Wellcome (090532, 098381, 106130, 203141, 212259); NIH (U01-DK105535). PWF is supported by an IRC award from the Swedish Foundation for Strategic Research and a European Research Council award ERC-2015-CoG - 681742_NASCENT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study protocol was obtained from each of the regional research ethics review boards separately (Lund, Sweden: 20130312105459927, Copenhagen, Denmark: H-1-2012-166 and H-1-2012-100, Amsterdam, Netherlands: NL40099.029.12, Newcastle, Dundee and Exeter, UK: 12/NE/0132), and all participants provided written informed consent at enrolment. The research conformed to the ethical principles for medical research involving human participants outlined in the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors agree to make data and materials supporting the results or analyses presented in their paper available upon reasonable request
|
|
4. |
- Ferreira, Duarte M. S., et al.
(författare)
-
LIM and cysteine-rich domains 1 (LMCD1) regulates skeletal muscle hypertrophy, calcium handling, and force
- 2019
-
Ingår i: Skeletal Muscle. - : BioMed Central. - 2044-5040. ; 9:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Skeletal muscle mass and strength are crucial determinants of health. Muscle mass loss is associated with weakness, fatigue, and insulin resistance. In fact, it is predicted that controlling muscle atrophy can reduce morbidity and mortality associated with diseases such as cancer cachexia and sarcopenia.Methods: We analyzed gene expression data from muscle of mice or human patients with diverse muscle pathologies and identified LMCD1 as a gene strongly associated with skeletal muscle function. We transiently expressed or silenced LMCD1 in mouse gastrocnemius muscle or in mouse primary muscle cells and determined muscle/cell size, targeted gene expression, kinase activity with kinase arrays, protein immunoblotting, and protein synthesis levels. To evaluate force, calcium handling, and fatigue, we transduced the flexor digitorum brevis muscle with a LMCD1-expressing adenovirus and measured specific force and sarcoplasmic reticulum Ca2+ release in individual fibers. Finally, to explore the relationship between LMCD1 and calcineurin, we ectopically expressed Lmcd1 in the gastrocnemius muscle and treated those mice with cyclosporine A (calcineurin inhibitor). In addition, we used a luciferase reporter construct containing the myoregulin gene promoter to confirm the role of a LMCD1-calcineurin-myoregulin axis in skeletal muscle mass control and calcium handling.Results: Here, we identify LIM and cysteine-rich domains 1 (LMCD1) as a positive regulator of muscle mass, that increases muscle protein synthesis and fiber size. LMCD1 expression in vivo was sufficient to increase specific force with lower requirement for calcium handling and to reduce muscle fatigue. Conversely, silencing LMCD1 expression impairs calcium handling and force, and induces muscle fatigue without overt atrophy. The actions of LMCD1 were dependent on calcineurin, as its inhibition using cyclosporine A reverted the observed hypertrophic phenotype. Finally, we determined that LMCD1 represses the expression of myoregulin, a known negative regulator of muscle performance. Interestingly, we observed that skeletal muscle LMCD1 expression is reduced in patients with skeletal muscle disease.Conclusions: Our gain- and loss-of-function studies show that LMCD1 controls protein synthesis, muscle fiber size, specific force, Ca2+ handling, and fatigue resistance. This work uncovers a novel role for LMCD1 in the regulation of skeletal muscle mass and function with potential therapeutic implications.
|
|